Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 23, Issue 2, 2016, Pages 150-156

  Quispe, Renato ^a   Martin, Seth S ^a,b   Jones, Steven R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Diabetes Mellitus; High Density Lipoprotein Cholesterol; Insulin Resistance; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REVIEW; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; OBESITY; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 84960119232     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000241     Document Type: Review

References (86)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491-497.
2. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world: A growing challenge. N Engl J Med 2007; 356:213-215.
3. Hu G, Tuomilehto J, Silventoinen K, et al. Joint effects of physical activity, body mass index, waist circumference and waist-To-hip ratio with the risk of cardiovascular disease among middle-Aged Finnish men and women. Eur Heart J 2004; 25:2212-2219.
4. Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-To-hip ratio on the risk of heart failure. Circulation 2010; 121:237-244.
5. Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vasc Dis Res 2005; 2:105-112.
6. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-Analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-414.
7. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-Alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
8. Emanuela F, Grazia M, Marco de R, et al. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012; 2012:476380.
9. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
10. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-1297.
11. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy-part I. Eur Heart J 2013; 34:2436-2443.
12. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34:3035-3087.
13. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
14. Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980; 1:1373-1376.
15. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364-1379.
16. Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-Analysis of 102 prospective studies. Lancet 2010; 375:2215-2222.
17. Faerch K, Vaag A, Holst JJ, et al. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: The Inter99 study. Diabetes Care 2009; 32:439-444.
18. Kim SH, Reaven GM. Isolated impaired fasting glucose and peripheral insulin sensitivity: not a simple relationship. Diabetes Care 2008; 31:347-352.
19. Gast KB, Tjeerdema N, Stijnen T, et al. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-Analysis. PLoS One 2012; 7:e52036.
20. Uetani T, Amano T, Harada K, et al. Impact of insulin resistance on postprocedural myocardial injury and clinical outcomes in patients who underwent elective coronary interventions with drug-eluting stents. JACC Cardiovasc Interv 2012; 5:1159-1167.
21. Jones CN, Abbasi F, Carantoni M, et al. Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Am J Physiol Endocrinol Metab 2000; 278:E501-E508.
22. McLaughlin T, Abbasi F, Kim HS, et al. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism 2001; 50:795-800.
23. Abbasi F, Brown BW Jr, Lamendola C, et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40:937-943.
24. Lenzen M, Ryden L, Ohrvik J, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: A report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006; 27:2969-2974.
25. Action to Control Cardiovascular Risk in Diabetes Study G. Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
26. Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol 2012; 10:684-686.
27. Adiels M, Boren J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005; 25:1697-1703.
28. Boren J, Watts GF, Adiels M, et al. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. Arterioscler Thromb Vasc Biol 2015; 35:2218-2224.
29. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism 2014; 63:1469-1479.
30. Saleh J, Sniderman AD, Cianflone K. Regulation of Plasma fatty acid metabolism. Clin Chim Acta 1999; 286:163-180.
31. Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 2011; 31:2144-2150.
32. Quispe R, Manalac RJ, Faridi KF, et al. Relationship of the triglyceride to highdensity lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis 2015; 242:243-250.
33. Sniderman AD, Wolfson C, Teng B, et al. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982; 97:833-839.
34. Guerin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL (1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001; 21:282-288.
35. Drew BG, Rye KA, Duffy SJ, et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8:237-245.
36. Anderwald C, Anderwald-Stadler M, Promintzer M, et al. The Clamp-Like Index: A novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care 2007; 30:2374-2380.
37. Alberti KG, Zimmet P, Shaw J; Group IDFETFC. The metabolic syndrome: A new worldwide definition. Lancet 2005; 366:1059-1062.
38. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
39. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulinmediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23:171-175.
40. Reaven G. Wanted!: A standardized measurement of plasma insulin concentration. Arterioscler Thromb Vasc Biol 2011; 31:954-955.
41. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992; 231:25-30.
42. Meigs JB, Williams K, Sullivan LM, et al. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 2004; 27:1417-1426.
43. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109:433-438.
44. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802-809.
45. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96:399-404.
46. Li C, Ford ES, Meng YX, et al. Does the association of the triglyceride to highdensity lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovasc Diabetol 2008; 7:4.
47. Sumner AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 2008; 196:696-703.
48. Salazar MR, Carbajal HA, Espeche WG, et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol 2012; 109:1749-1753.
49. Sumner AE, Finley KB, Genovese DJ, et al. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005; 165:1395-1400.
50. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45:1345-1352.
51. Triglyceride Coronary Disease Genetics C. Emerging Risk Factors C. Sarwar N, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375:1634-1639.
52. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
53. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142-2152.
54. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: The Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011; 270:65-75.
55. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61:427-436.
56. Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128:1298-1309.
57. Hopkins PN, Nanjee MN, Wu LL, et al. Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study. Atherosclerosis 2009; 207:559-566.
58. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-Term risk of ischemic heart disease in men: 13-year followup data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25:553-559.
59. Gaziano JM, Hennekens CH, ODonnell CJ, et al. Fasting triglycerides, highdensity lipoprotein, and risk of myocardial infarction. Circulation 1997; 96:2520-2525.
60. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17:1114-1120.
61. de Leon AC, Coello SD, Gonzalez DA, et al. Impaired fasting glucose, ancestry and waist-To-height ratio: main predictors of incident diagnosed diabetes in the Canary Islands. Diabet Med 2012; 29:399-403.
62. Hadaegh F, Khalili D, Ghasemi A, et al. Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men. Nutr Metab Cardiovasc Dis 2009; 19:401-408.
63. Salazar MR, Carbajal HA, Espeche WG, et al. Identifying cardiovascular disease risk and outcome: use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Intern Med 2013; 273:595-601.
64. Salazar MR, Carbajal HA, Espeche WG, et al. Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular disease in hypertensive subjects. J Am Soc Hypertens 2014; 8:724-731.
65. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high highdensity lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161:361-366.
66. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005; 28:1769-1778.
67. Wilson PW, DAgostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066-3072.
68. Marotta T, Russo BF, Ferrara LA. Triglyceride-To-HDL-cholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients. Obesity (Silver Spring) 2010; 18:1608-1613.
69. Masley SC, Roetzheim R, Masley LV, et al. Emerging risk factors as markers for carotid intima media thickness scores. J Am Coll Nutr 2015; 34:100-107.
70. Lorenzo C, Hartnett S, Hanley AJ, et al. Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: The insulin resistance atherosclerosis study. J Clin Endocrinol Metab 2013; 98:1622-1630.
71. Robins SJ, Lyass A, Zachariah JP, et al. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: The Framingham Heart Study. Arterioscler Thromb Vasc Biol 2011; 31:1208-1214.
72. Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003; 26:1513-1517.
73. Kannel WB, Vasan RS, Keyes MJ, et al. Usefulness of the triglyceride-highdensity lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol 2008; 101:497-501.
74. Weis U, Turner B, Gibney J, et al. Long-Term predictors of coronary artery disease and mortality in type 1 diabetes. QJM 2001; 94:623-630.
75. Laverdy OG, Hueb WA, Sprandel MC, et al. Effects of glycemic control upon serum lipids and lipid transfers to HDL in patients with type 2 diabetes mellitus: novel findings in unesterified cholesterol status. Exp Clin Endocrinol Diabetes 2015; 123:232-239.
76. Zonszein J, Lombardero M, Ismail-Beigi F, et al. Triglyceride high-density lipoprotein ratios predict glycemia-lowering in response to insulin sensitizing drugs in type 2 diabetes: A post hoc analysis of the BARI 2D. J Diabetes Res 2015; 2015:129891.
77. Chait A, Bierman EL, Albers JJ. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest 1979; 64:1309-1319.
78. Emanuele N, Azad N, Abraira C, et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med 1998; 158:2485-2490.
79. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995; 18:843-851.
80. Palamaner Subash Shantha G. Kumar AA, Kahan S, Irukulla PK, Cheskin LJ. Triglyceride/HDL ratio as a screening tool for predicting success at reducing antidiabetic medications following weight loss. PLoS One 2013; 8:e69285.
81. Harder H, Dinesen B, Astrup A. The effect of a rapid weight loss on lipid profile and glycemic control in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 2004; 28:180-182.
82. Rafraf M, Zemestani M, Asghari-Jafarabadi M. Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes. J Endocrinol Invest 2015; 38:163-170.
83. Farnsworth E, Luscombe ND, Noakes M, et al. Effect of a high-protein, energyrestricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am J Clin Nutr 2003; 78:31-39.
84. Li SC, Liu YH, Liu JF, et al. Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes mellitus. Metabolism 2011; 60:474-479.
85. Parker B, Noakes M, Luscombe N, Clifton P. Effect of a high-protein, highmonounsaturated fat weight loss diet on glycemic control and lipid levels in type 2 diabetes. Diabetes Care 2002; 25:425-430.
86. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549-2557.